PRLD实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients...

Stats
今日成交量	16 717.00
平均成交量	67 156.00
市值	261.60M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-0.470 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.910
ATR14	$0.0360 (0.93%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Huang Jane	Sell	9 375	Restricted Stock Unit
2024-04-04	Huang Jane	Buy	9 375	Common Stock
2024-04-04	Huang Jane	Sell	3 347	Common Stock
2024-03-01	Lim Bryant David	Buy	150 000	Employee Stock Option (right to buy)
2024-03-01	Scherle Peggy	Buy	150 000	Employee Stock Option (right to buy)

INSIDER POWER
99.32
Last 98 transactions
Buy: 26 942 964 \| Sell: 353 466

音量相关性

長: -0.12 (neutral)

短: 0.02 (neutral)

Signal:(44.791) Neutral

Prelude Therapeutics 相关性

10 最正相关
XOS	0.828
RNDM	0.817

10 最负相关
BNIXU	-0.842

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Prelude Therapeutics 相关性 - 货币/商品

-0.50
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

-0.68
( moderate negative )

0.48
( neutral )

0.38
( neutral )

Prelude Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2023
营收:	$0
毛利润:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2022
营收:	$0
毛利润:	$-3.04M (0.00 %)
EPS:	$-2.27

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.43

Financial Reports:

No articles found.

Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.